Start-Upomics

A collection of 28 posts

Paid-members only

Start-Upomics

Dante Genomics rebrands as Dante Omics AI

Paid-members only

Start-Upomics

Let's Get Checked buys TruePill to take on end-to-end at home healthcare

Paid-members only

Start-Upomics

Guardant Co-CEO's million dollar bet roils patients, employees and anyone with two functioning brain cells

Paid-members only

Nanopore Wars

Holey Pores, BGI has been working on nanopore sequencing!

Paid-members only

Start-Upomics

Illumina recently courted investors with a presentation on how their new product R&D pipeline is going to resurrect the Illumina stock price

Paid-members only

Start-Upomics

Nabsys is back, baby!

Paid-members only

Start-Upomics

The 23andMe board tells Anne Wojcicki to do better in her attempt to take 23andMe private after a rocky 3 years as a public company

Paid-members only

Start-Upomics

Dual barcodes spark a duel between Molecular Loop and Illumina

Paid-members only

Protein Sequencing

There are a lot of companies working on protein sequencing, so who is in the lead?

Paid-members only

Start-Upomics

Everything that happened this week in short-reads

Paid-members only

Start-Upomics

The Grail/Illumina Class-Action lawsuit gets a juicy update

Paid-members only

Start-Upomics

Tempus' good very bad week included a $410m IPO, a lawsuit and a ~$20 swing in their post-IPO stock price

Paid-members only

High-Throughput Sequencing

If you thought the sequencing wars were hot already, have you considered what a $10 genome might do to them?

Paid-members only

Start-Upomics

Who's prioritizing bringing the next generation of sequencing technology to the clinic? The answer might surprise you.

Paid-members only

Start-Upomics

Grail might have been too bold a choice for a company name

Paid-members only

Genetics

What happens if insurance companies start using your genetic data against you?

Paid-members only

Genomics Featured

Pacific Biosciences drops nearly 50% after a bad earnings report and a mind-boggling update to their product roadmap

Paid-members only

Start-Upomics Featured

Sighs of relief are heard as Carl Icahn's director steps down from Illumina's board

Paid-members only

Start-Upomics Featured

Bionano Genomics recently announced it was laying off 1/3rd of its workforce

Paid-members only

Start-Upomics Featured

Reports of NanoString's death appear to have been severely overstated

Paid-members only

Genomic Sequencing Featured

Illumina ruffled some feathers this week with a video appeal to moderate sized "core labs"

Paid-members only

Start-Upomics Featured

Francis deSouza is back from his post-Illumina purgatory with a new AI start-up

Paid-members only

Start-Upomics Featured

Is the life sciences bankruptcy bloodbath waxing or waning? Let's hope Nanostring and Invitae aren't emblematic of what's to come!

Paid-members only

Start-Upomics Featured

RavGen got Natera to cough up $57m. What's going on with non-invasive screening test IP?

Paid-members only

Start-Upomics Featured

23andMe has been in the news recently about a data breach, raising important questions about data security in the age of genomics